Roots Analysis names five leading biopharmaceutical excipient manufacturers
Roots Analysis has released a study identifying five key manufacturers of biopharmaceutical excipients. These companies are critical for the stability and efficacy of biologic drugs.
Market research firm Roots Analysis has published a report identifying the five foremost manufacturers of biopharmaceutical excipients. The report highlights the increasing importance of excipients in the development of protein therapeutics, vaccines, and other biologic drugs, where they directly impact product stability, shelf life, and efficacy.
The study evaluated manufacturers based on several criteria, including the breadth of their product portfolios, relevance to biologic formulations, manufacturing capabilities, quality control, regulatory support, global reach, and recent investment activity. The identified leading companies are BASF, Croda Pharma, Evonik, Merck KGaA, and Roquette.
Demands on biopharmaceutical excipients have significantly escalated. Drug developers require ingredients with tightly controlled impurity profiles, low bioburden and endotoxin levels, and consistent batch-to-batch quality. Transparent supply chains and comprehensive regulatory documentation are also essential, alongside technical support throughout the formulation process.
In response to these demands, many companies have invested in Good Manufacturing Practice (GMP) compliant facilities and developed specialized portfolios of high-purity surfactants, amino acids, sugars, polyols, polymers, vaccine adjuvants, and lipid-based delivery materials. Roots Analysis' report provides detailed insights into these companies' capabilities and market outlook for the next decade.